Glaucoma & Eye Health: Latest Medical Cannabis Research

Recent Glaucoma and Eye Health Research

Medical cannabis continues to be a topic of interest for patients with glaucoma and other eye conditions. Below, we share findings from recent peer-reviewed studies published on PubMed, the U.S. National Library of Medicine's database of scientific research. While these studies offer insights, they do not provide medical advice. Always consult your physician before making changes to your treatment plan.

Study 1: Dronabinol and Ocular Blood Flow in Glaucoma Patients

A 2023 study in Acta Ophthalmologica investigated whether dronabinol—a synthetic form of THC—could improve ocular blood flow in patients with primary open-angle glaucoma (POAG). Researchers conducted a randomized, double-masked, placebo-controlled trial with 23 participants. After a single oral dose of dronabinol, they measured changes in blood flow to the eye.

The study found that dronabinol increased ocular blood flow in some patients, suggesting a potential benefit for those with glaucoma. However, the researchers noted that further studies are needed to confirm these findings and determine long-term effects.

Study 2: Geroprotective Agents and Ocular Health

Glaucoma and other retinal diseases, such as age-related macular degeneration (AMD) and diabetic retinopathy (DR), are influenced by aging. A 2024 study in the Journal of Ocular Pharmacology and Therapeutics explored the role of geroprotective agents—including glucagon-like peptide-1 (GLP-1) receptor agonists—in slowing age-related ocular decline.

While this study did not focus solely on cannabis, it highlighted how compounds that influence cellular aging may help protect retinal health. The authors suggested that further research could explore whether cannabis-derived compounds have similar effects.

Study 3: CBD and Intraocular Pressure in Horses

Cannabidiol (CBD) has been studied for its potential effects on intraocular pressure (IOP), a key factor in glaucoma. A 2024 study in Veterinary Ophthalmology examined whether oral CBD affected IOP in healthy horses. Researchers gave horses either CBD or a placebo for three days and measured IOP at multiple time points.

The study found that CBD did not significantly lower IOP in horses, suggesting that its effects on eye pressure may differ across species. While this study focused on animals, it underscores the need for more research in humans before drawing conclusions about CBD’s role in glaucoma treatment.

Study 4: Cannabis, Nicotine, and Ocular Inflammation

Ocular inflammatory diseases, such as uveitis, can lead to vision loss. A 2024 study in the Journal of Current Ophthalmology analyzed whether cannabis or nicotine use was associated with an increased risk of these conditions.

Using data from the TriNetX database, researchers compared patients with and without a history of cannabis, cigarette, or vaping use. They found that cannabis use was not significantly linked to a higher risk of ocular inflammation, while nicotine use was. This suggests that cannabis may not contribute to the same inflammatory risks as tobacco.

Study 5: Therapeutic Drug Monitoring of Cannabinoids

A 2024 study in Pharmacopsychiatry examined how cannabinoids like THC and CBD are metabolized in the body. Researchers reviewed existing studies on blood concentration levels and their relationship to clinical effects.

The study highlighted the variability in how individuals process cannabinoids, emphasizing the need for personalized dosing in medical cannabis treatment. While this research did not focus specifically on eye health, it provides important context for understanding how cannabis may interact with glaucoma and other conditions.

What This Means for Patients

These studies offer preliminary insights into how cannabis compounds may interact with eye health and glaucoma. However, the science is still evolving, and more research is needed to determine the role of medical cannabis in managing these conditions.

If you’re considering medical cannabis for glaucoma or another eye condition, speak with your physician to discuss potential benefits, risks, and how it may fit into your treatment plan.